Searchable abstracts of presentations at key conferences in endocrinology

ea0070ep130 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Similar effect of tocilizumab, an interleukin-6 receptor antagonist, administered either intravenously or subcutaneously on lipid levels in rheumatoid arthritis

Athanassiou Panagiotis , Athanassiou Lambros , Tzanavari Aikaterini , Gatsiou Marina , Devetzi Eirini , Tsakiridis Pavlos , Mavroudi Maria , Kostoglou-Athanassiou Ifigenia

Tocilizumab is an interleukin-6 receptor antagonist used in the treatment of rheumatoid arthritis (RA). It is known to induce remission and inhibit radiographic progression in RA. Tocilizumab may be administered either intravenously or subcutaneously. Its effect on lipid levels and the cardiovascular risk has not been fully investigated. The aim was to study the effect of tocilizumab administered either iv or sc on disease activity, lipid levels and cardiovascular risk in RA p...

ea0070aep429 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

The management of nonalcoholic fatty liver disease with a choline containing antioxidant compound

Athanassiou Panagiotis , Athanassiou Lambros , Kotrotsios Anastasios , Gatsiou Marina , Tsakiridis Pavlos , Devetzi Eirini , Mavroudi Maria , Kaiafa Georgia , Savopoulos Christos , Kostoglou-Athanassiou Ifigenia

Nonalcoholic fatty liver disease has an increased worldwide prevalence due to obesity and the use of various drugs affecting the liver. The pathogenesis of nonalcoholic fatty liver disease is presently not completely defined. In addition, there is a paucity of agents for its treatment. Choline deficiency has been shown to induce nonalcoholic liver disease. Systemic autoimmune rheumatic diseases require chronic systemic treatment with various agents, which may affect liver func...